Edition:
United States

Momenta Pharmaceuticals Inc (MNTA.O)

MNTA.O on Nasdaq

17.15USD
22 Sep 2017
Change (% chg)

$0.35 (+2.08%)
Prev Close
$16.80
Open
$16.75
Day's High
$17.20
Day's Low
$16.65
Volume
510,672
Avg. Vol
677,835
52-wk High
$19.90
52-wk Low
$10.75

Select another date:

Wed, Aug 2 2017

BRIEF-Momenta Pharmaceuticals posts Q2 loss per share $0.50

* Momenta pharmaceuticals reports second quarter 2017 financial results and provides corporate update

BRIEF-Amphastar announces jury verdict in litigation against Momenta Pharmaceuticals and Sandoz Inc

* Amphastar announces jury verdict in patent litigation against Momenta Pharmaceuticals Inc and Sandoz Inc

U.S. jury sides with Amphastar over Momenta in drug patent trial

BOSTON A federal jury handed Amphastar Pharmaceuticals Inc a big win on Friday after it was accused of infringing on a patent held by Momenta Pharmaceuticals Inc through its production of a generic version of the blood-thinner Lovenox.

U.S. jury sides with Amphastar over Momenta in drug patent trial

BOSTON A federal jury handed Amphastar Pharmaceuticals Inc a big win on Friday after it was accused of infringing on a patent held by Momenta Pharmaceuticals Inc through its production of a generic version of the blood-thinner Lovenox.

UPDATE 2-U.S. jury sides with Amphastar over Momenta in drug patent trial

BOSTON, July 21 A federal jury handed Amphastar Pharmaceuticals Inc a big win on Friday after it was accused of infringing on a patent held by Momenta Pharmaceuticals Inc through its production of a generic version of the blood-thinner Lovenox.

U.S. jury sides with Amphastar over Momenta in drug patent trial

BOSTON, July 21 Amphastar Pharmaceuticals Inc on Friday won a trial in a lawsuit claiming that the drugmaker through its production of a generic version of the blood-thinner Lovenox infringed a patent held by Momenta Pharmaceuticals Inc.

Momenta seeks $938 million from Amphastar at drug patent trial's end

A lawyer for Momenta Pharmaceuticals Inc urged a federal jury on Thursday to force Amphastar Pharmaceuticals Inc to pay $938 million for infringing a patent the drugmaker held through its production of a generic version of the blood-thinner Lovenox.

Momenta, Sandoz face off with Amphastar in blockbuster drug patent trial

Momenta Pharmaceuticals Inc and Novartis AG's Sandoz unit took Amphastar Pharmaceuticals Inc to trial Tuesday in a long-running suit over patent infringement that seeks hundreds of millions of dollars in damages over Amphastar's generic version of the blockbuster blood-thinner Lovenox.

BRIEF-Momenta Pharmaceuticals appoints Santiago Arroyo as chief medical officer

* Momenta Pharmaceuticals appoints Santiago Arroyo, M.D., Ph.D. as chief medical officer Source text for Eikon: Further company coverage:

BRIEF-Momenta Pharmaceuticals Q1 loss per share $0.46

* Momenta pharmaceuticals reports first quarter 2017 financial results

Select another date: